CROs/Service Providers

Pharmaron acquires Quotient Bioresearch

Friday, February 5, 2016

Pharmaron, a fully integrated CRO offering laboratory and manufacturing services for pharmaceutical and biotech research and development, has acquired Quotient Bioresearch. Quotient, a U.K.-based CRO with more than 200 employees, focuses on integrating radiochemistry and metabolism. Part of this expertise is derived from Quotient’s previous acquisition of GE Amersham’s radiosynthesis business.

[Read More]

BioClinica announces post-approval research service

Tuesday, February 2, 2016

BioClinica, a specialty clinical trials services and technology provider, has launched its newest service line offering. The Post-Approval Research division of its Global Clinical Research business segment was created to meet the rapidly growing and ever-evolving needs of the post-approval research industry.

[Read More]

Icon releases Flex Advantage for patient randomization

Tuesday, February 2, 2016

Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has launched Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomization and clinical supply management capabilities and supports the execution of adaptive trials.

[Read More]

CROs begin consolidating site landscape

Monday, February 1, 2016

Major trends in drug development will reshape the global investigative site landscape. Trends to look out for include patient centricity and big data to CROs assuming responsibility for site effectiveness and patient recruitment.

[Read More]

BioClinica acquires Clinverse

Monday, January 25, 2016

BioClinica, a specialty clinical trials services and technology provider, has acquired Clinverse. The acquisition expands Bioclinica’s offerings into the growing market of automated financial management technology solutions for global clinical trials. Clinverse is the latest investment that Bioclinica has completed to build the company into a leading provider of solutions that bring quality and efficiency to every phase of clinical trial development.  

[Read More]

Parexel to acquire Health Advances

Wednesday, January 20, 2016

Parexel International, a global biopharmaceutical services organization, has entered into a definitive agreement to acquire all outstanding equity securities of Health Advances, an independent life sciences strategy consulting firm. Health Advances combines clinical, scientific and business expertise to provide strategic advice to executives leading life sciences companies and investors.

[Read More]

WuXi AppTec plans $120M integrated biologics solution center

Tuesday, January 19, 2016

WuXi AppTec, an open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, has started construction of a state-of-the-art integrated biologics solution center at the company’s headquarters in Shanghai.  The company plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, which will be operational in 2017 and accommodate 800 scientists. The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development and clinical manufacturing on a consolidated campus. 

[Read More]